Abstract
As well known, infertility is a prevalent presenting feature of PCOS with ~75% of these women suffering infertility due to anovulation, making PCOS the most common cause of anovulatory infertility. Women with PCOS often have many concerns about childbearing including whether they could become pregnant and what they should do before they try to become pregnant. Polycystic ovary syndrome (PCOS) is a common female reproductive endocrine disease. The prevalence in premenopausal women ranges from 6 to 20%, possibly making this syndrome as the most common endocrine and metabolic disorder in women of reproductive age [1–3]. According to the reports in specialized departments of China like in our “Department of Gynecological Endocrinology,” it stands as the most important disease – in our daily clinic from more than 500 outpatients, at least 50% are diagnosed with PCOS, and more than 50,000 per year of our PCOS patients get treatment as described in this chapter. The disease can begin in early adolescence, the etiology is not yet clear, the pathogenesis is complex, and it is related to environmental (especially nutrition) factors. Particularly, genetical factors may also play an important role in the development of the disease and differences in type and outcome [4]. Changes of endocrine and metabolic markers are often associated with PCOS although are not decisive for the diagnosis. In 2003, the “European Society for Human Reproduction and Embryology (ESHRE)” and the “American Society of Reproductive Medicine (ASRM)” revised the diagnostic criteria for PCOS at the Rotterdam meeting [5]: (1) rare ovulation or anovulation; (2) abnormal clinical manifestations and/or biochemical indicators of hyperandrogenism; and (3) polycystic ovarian morphology (PCOM): follicle number of 2–9 mm in diameter in one or both ovaries ≥12 and/or ovarian volume >10 cm3. In 2018 the cut-off for follicle number was raised to 20 or more in either ovary [2]. If at least two of the three abovementioned criteria are met, “PCOS” can be diagnosed, whereby diseases such as thyroid dysfunction, Cushing’s syndrome, androgen-secreting tumors, hyper-prolactinemia, pituitary gland diseases, and premature ovarian failure must be excluded.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol. 2018;14:270–84.
Teede HJ, Misso ML, Costello MF, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2018;33:1602–18.
Chen Z, Tian Q, Qiao J, et al. Guidelines for the diagnosis and treatment of polycystic ovary syndrome in China. Chinese J Obst Gynecol. 2018;53(1):2–6.
Conway G, Dewailly D, Diamanti-Kandarakis E, et al. The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. Eur J Endocrinol. 2014;171:P1–29.
EA-SPcwg R (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81:19–25.
Tian X, Ruan X, Mueck AO, et al. Anti-Mullerian hormone levels in women with polycystic ovarian syndrome compared with normal women of reproductive age in China. Gynecol Endocrinol. 2014;30:126–9.
Tian X, Ruan X, Mueck AO, et al. Serum anti-Mullerian hormone and insulin resistance in the main phenotypes of non-obese polycystic ovarian syndrome women in China. Gynecol Endocrinol. 2014;30:836–9.
Jin J, Ruan X, Hua L, et al. Prevalence of diminished ovarian reserve in Chinese women with polycystic ovary syndrome and sensitive diagnostic parameters. Gynecol Endocrinol. 2017;33:694–7.
Cassar S, Teede HJ, Moran LJ, et al. Polycystic ovary syndrome and anti-Mullerian hormone: role of insulin resistance, androgens, obesity and gonadotrophins. Clin Endocrinol. 2014;81:899–906.
Ruan X, Kubba A, Aguilar A, et al. Use of cyproterone acetate/ethinylestradiol in polycystic ovary syndrome: rationale and practical aspects. Eur J Contracept Reprod Health Care. 2017;22(3):183–90.
Sirmans SM, Pate KA. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol. 2014;6:1–13.
Fauser BCJM, Tarlatzis BC, Rebar RW, et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-sponsored 3rd PCOS consensus workshop group. Fertil Steril. 2012;97:28–38.
Badawy AS, Elnashar A. Treatment options for polycystic ovary syndrome. Int J Women's Health. 2011;3:25–35.
Poretsky L, Piper B. Insulin resistance, hypersensitivity of LH, and dual defect hypothesis for the pathogenesis of polycystic ovary syndrome. Obstet Gynecol. 1994;84:613–21.
McCartney CR, Eagleson CR, Marshall JC. Regulation of gonadotropin secretion: implications for polycystic ovary syndrome. Semin Reprod Med. 2002;20:317–36.
Lizneva D, Suturina L, Walker W, et al. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril. 2016;106:6–15.
Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev. 2012;33:981–1030.
Norman RJ, Dewailly D, Legro RS, et al. Polycystic ovary syndrome. Lancet. 2007;370:685–97.
Ruan X, Mueck AO. Oral contraception for women of middle age. Maturitas. 2015;82:266–70.
Lim SS, Davies MJ, Norman RJ, et al. Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2012;18:618–37.
Dumesic DA, Akopians AL, Madrigal VK, et al. Hyperandrogenism accompanies increased intra-abdominal fat storage in Normal weight polycystic ovary syndrome women. J Clin Endocrinol Metab. 2016;101:4178–88.
Arpaci D, Gurkan Tocoglu A, et al. The relationship between epicardial fat tissue thickness and visceral adipose tissue in lean patients with polycystic ovary syndrome. J Ovarian Res. 2015;8:71.
Ollila MM, West S, Keinanen-Kiukaaniemi S, et al. Overweight and obese but not normal weight women with PCOS are at increased risk of type 2 diabetes mellitus-a prospective population-based cohort study. Hum Reprod. 2017;32:968.
Delitala AP, Capobianco G, Delitala G, et al. Polycystic ovary syndrome, adipose tissue and metabolic syndrome. Arch Gynecol Obstet. 2017;296:405–19.
Legro RS, Dodson WC, Kunselman AR, et al. Benefit of delayed fertility therapy with preconception weight loss over immediate therapy in obese women with PCOS. J Clin Endocrinol Metab. 2016;101:2658–66.
Zhao Y, Ruan X, Mueck AO. Letrozole combined with low dose highly purified HMG for ovulation induction in clomiphene citrate-resistant infertile Chinese women with polycystic ovary syndrome: a prospective study. Gynecol Endocrinol. 2017;33:462–6.
Legro RS, Dodson WC, Kris-Etherton PM, et al. Randomized controlled trial of preconception interventions in infertile women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2015;100:4048–58.
Wu H, Ruan X, Jin J, et al. Metabolic profile of Diane-35 versus Diane-35 plus metformin in Chinese PCOS women under standardized life-style changes. Gynecol Endocrinol. 2015;31:548–51.
Dokras A, Sarwer DB, Allison KC, et al. Weight loss and lowering androgens predict improvements in health-related quality of life in women with PCOS. J Clin Endocrinol Metab. 2016;101:2966–74.
Riley JK, Jungheim ES. Is there a role for diet in ameliorating the reproductive sequelae associated with chronic low-grade inflammation in polycystic ovary syndrome and obesity? Fertil Steril. 2016;106:520–7.
McKinnon CJ, Hatch EE, Rothman KJ, et al. Body mass index, physical activity and fecundability in a north American preconception cohort study. Fertil Steril. 2016;106:451–9.
Song J, Ruan X, Gu M, et al. Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance. Gynecol Endocrinol. 2018;34:413–7.
Ruan X, Song J, Gu M, et al. Effect of Diane-35, alone or in combination with orlistat or metformin in Chinese polycystic ovary syndrome patients. Arch Gynecol Obstet. 2018;297:1557–63.
Escobar-Morreale HF, Santacruz E, Luque-Ramirez M, et al. Prevalence of 'obesity-associated gonadal dysfunction' in severely obese men and women and its resolution after bariatric surgery: a systematic review and meta-analysis. Hum Reprod Update. 2017;23:390–408.
Lo JC, Feigenbaum SL, Yang J, et al. Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91:1357–63.
Cassar S, Misso ML, Hopkins WG, et al. Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic-hyperinsulinaemic clamp studies. Hum Reprod. 2016;31:2619–31.
Benham JL, Yamamoto JM, Friedenreich CM, et al. Role of exercise training in polycystic ovary syndrome: a systematic review and meta-analysis. Clin Obes. 2018;8:275–84.
American Diabetes Association. Management of diabetes in pregnancy. Diabetes Care. 2017;40(Suppl 1):S114–9.
Anagnostis P, Tarlatzis BC, Kauffman RP. Polycystic ovarian syndrome (PCOS): long-term metabolic consequences. Metabolism. 2018;86:33–43.
Katulski K, Czyzyk A, Podfigurna-Stopa A, et al. Pregnancy complications in polycystic ovary syndrome patients. Gynecol Endocrinol. 2015;31:87–91.
Qin JZ, Pang LH, Li MJ, et al. Obstetric complications in women with polycystic ovary syndrome: a systematic review and meta-analysis. Reprod Biol Endocrinol. 2013;11:56.
Naver KV, Grinsted J, Larsen SO, et al. Increased risk of preterm delivery and pre-eclampsia in women with polycystic ovary syndrome and hyperandrogenaemia. BJOG. 2014;121:575–81.
Li Y, Ruan X, Wang H, et al. Comparing the risk of adverse pregnancy outcomes of Chinese patients with polycystic ovary syndrome with and without antiandrogenic pretreatment. Fertil Steril. 2018;109:720–7.
Acknowledgments
Supported by Beijing Municipal Administration of Hospitals’ Ascent Plan (DFL20181401), Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support (XMLX201710).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 International Society of Gynecological Endocrinology
About this chapter
Cite this chapter
Ruan, X., Mueck, A.O. (2021). Management of PCOS Women Preparing Pregnancy. In: Genazzani, A.R., Ibáñez, L., Milewicz, A., Shah, D. (eds) Impact of Polycystic Ovary, Metabolic Syndrome and Obesity on Women Health. ISGE Series. Springer, Cham. https://doi.org/10.1007/978-3-030-63650-0_11
Download citation
DOI: https://doi.org/10.1007/978-3-030-63650-0_11
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-63649-4
Online ISBN: 978-3-030-63650-0
eBook Packages: MedicineMedicine (R0)